Rugo, Hope S. http://orcid.org/0000-0001-6710-4814
Van Poznak, Catherine H. http://orcid.org/0000-0001-5523-6908
Neven, Patrick http://orcid.org/0000-0002-1434-9460
Danielewicz, Iwona http://orcid.org/0000-0002-5987-6272
Lee, Soo Chin http://orcid.org/0000-0002-5835-6419
Campone, Mario http://orcid.org/0000-0002-5196-5908
Chik, Jeannie Y. K.
Vega Alonso, Estela
Naume, Bjørn http://orcid.org/0000-0002-6811-9476
Brain, Etienne http://orcid.org/0000-0003-0881-9371
Siegel, Jonathan M. http://orcid.org/0000-0001-6477-4281
Li, Rui
Uema, Deise http://orcid.org/0000-0002-6883-6678
Wagner, Volker J.
Coleman, Robert E. http://orcid.org/0000-0002-4275-1043
Funding for this research was provided by:
Bayer HealthCare
Article History
Received: 2 May 2023
Accepted: 26 September 2023
First Online: 20 December 2023
Declarations
:
: HSR: Grants to institution from Astellas, AstraZeneca, Ayala, Boehringer Ingelheim, Daiichi, Gilead, Lilly, Macrogenics, Merck, Novartis, Pfizer, Polyphor, Roche, Seattle Genetics, and Sermonix; honoraria from Mylan, NAPO, Puma, and Samsung. CVP: Research grant from Bayer for a study outside of the one associated with this manuscript; royalties from UpToDate; board member (unpaid) of Cancer and Bone Society, an independent organization that promotes international collaborations within the cancer and bone field in both clinical and basic research. PN: Research funding from Kom op Tegen Kanker; consulting fees from AstraZeneca, Lilly, Novartis, Pfizer, and Roche; consulting or advisory roles for Lilly, Novartis, Pfizer, and Roche. ID, YKC, EVA, BN: No conflicts to disclose. SCL: Research grants from ACT Genomics, Eisai, Pfizer, and Taiho; consulting/advisory roles for, and payment/honoraria from, AstraZeneca, Daiichi-Sankyo, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and Roche; travel/meeting attendance support from Pfizer and Roche. MC: Payment and/or honoraria from Amgen, Gilead, GSK, Merck Sharp & Dohme, Novartis, Pfizer, and Seagen (to institution) and from Lilly, Pierre Fabre, and Sanofi (to self). EB: Consulting fees from Daiichi-Sankyo, Pfizer, and Sandoz; payment and/or honoraria from Eli Lilly, Pfizer, and Seagen; travel/meeting attendance support from Pfizer and Sandoz; consultancy/advisory role for Daiichi-Sankyo. JMS: Employee of Bayer; stock ownership in Bayer AG; leadership and/or committee roles in Pharmaceutical Industry Working Group on Estimands in Oncology, Society for Clinical Biostatistics Subcommittee for Statistics in Regulatory Affairs, and American Statistical Association. RL, DU, VW: Employee of Bayer. REC: Consulting fees from Sanofi; payment/honoraria from Amgen and Beigene; patent for MAF gene test and stock options with Inbiomotion; consultancy/advisory role for AstraZeneca.
: The study protocols and all protocol amendments were reviewed and approved by each study site’s independent ethics committee or institutional review board. The studies were conducted in accordance with all local legal and regulatory requirements and with the principles in the Declaration of Helsinki and the International Council for Harmonisation guideline E6: Good Clinical Practice.
: All patients signed an informed consent form before participation.
: Not applicable.